Marc de Garidel, CinCor Pharma CEO (Eric Piermont/AFP via Getty Images)

As­traZeneca bets up to $1.8B on Cin­Cor and its ex-Roche drug for hy­per­ten­sion

Cin­Cor Phar­ma’s hy­per­ten­sion drug may have failed a Phase II study, but that doesn’t scare As­traZeneca.

The phar­ma gi­ant is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA